These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

416 related articles for article (PubMed ID: 16193056)

  • 1. Structural basis of West Nile virus neutralization by a therapeutic antibody.
    Nybakken GE; Oliphant T; Johnson S; Burke S; Diamond MS; Fremont DH
    Nature; 2005 Sep; 437(7059):764-9. PubMed ID: 16193056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crystal structure of west nile virus envelope glycoprotein reveals viral surface epitopes.
    Kanai R; Kar K; Anthony K; Gould LH; Ledizet M; Fikrig E; Marasco WA; Koski RA; Modis Y
    J Virol; 2006 Nov; 80(22):11000-8. PubMed ID: 16943291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Fc region of an antibody impacts the neutralization of West Nile viruses in different maturation states.
    Lee PD; Mukherjee S; Edeling MA; Dowd KA; Austin SK; Manhart CJ; Diamond MS; Fremont DH; Pierson TC
    J Virol; 2013 Dec; 87(24):13729-40. PubMed ID: 24109224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A protective human monoclonal antibody targeting the West Nile virus E protein preferentially recognizes mature virions.
    Goo L; Debbink K; Kose N; Sapparapu G; Doyle MP; Wessel AW; Richner JM; Burgomaster KE; Larman BC; Dowd KA; Diamond MS; Crowe JE; Pierson TC
    Nat Microbiol; 2019 Jan; 4(1):71-77. PubMed ID: 30455471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A plant-produced vaccine protects mice against lethal West Nile virus infection without enhancing Zika or dengue virus infectivity.
    Lai H; Paul AM; Sun H; He J; Yang M; Bai F; Chen Q
    Vaccine; 2018 Mar; 36(14):1846-1852. PubMed ID: 29490880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The molecular basis of antibody-mediated neutralization of West Nile virus.
    Oliphant T; Diamond MS
    Expert Opin Biol Ther; 2007 Jun; 7(6):885-92. PubMed ID: 17555373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recovery of West Nile Virus Envelope Protein Domain III Chimeras with Altered Antigenicity and Mouse Virulence.
    McAuley AJ; Torres M; Plante JA; Huang CY; Bente DA; Beasley DWC
    J Virol; 2016 May; 90(9):4757-4770. PubMed ID: 26912625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of West Nile virus entry by using a recombinant domain III from the envelope glycoprotein.
    Chu JJH; Rajamanonmani R; Li J; Bhuvanakantham R; Lescar J; Ng ML
    J Gen Virol; 2005 Feb; 86(Pt 2):405-412. PubMed ID: 15659760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Type- and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes.
    Sukupolvi-Petty S; Austin SK; Purtha WE; Oliphant T; Nybakken GE; Schlesinger JJ; Roehrig JT; Gromowski GD; Barrett AD; Fremont DH; Diamond MS
    J Virol; 2007 Dec; 81(23):12816-26. PubMed ID: 17881453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutralization of West Nile virus by cross-linking of its surface proteins with Fab fragments of the human monoclonal antibody CR4354.
    Kaufmann B; Vogt MR; Goudsmit J; Holdaway HA; Aksyuk AA; Chipman PR; Kuhn RJ; Diamond MS; Rossmann MG
    Proc Natl Acad Sci U S A; 2010 Nov; 107(44):18950-5. PubMed ID: 20956322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A dynamic landscape for antibody binding modulates antibody-mediated neutralization of West Nile virus.
    Dowd KA; Jost CA; Durbin AP; Whitehead SS; Pierson TC
    PLoS Pathog; 2011 Jun; 7(6):e1002111. PubMed ID: 21738473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential expression of domain III neutralizing epitopes on the envelope proteins of West Nile virus strains.
    Li L; Barrett AD; Beasley DW
    Virology; 2005 Apr; 335(1):99-105. PubMed ID: 15823609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD4 T Cell Determinants in West Nile Virus Disease and Asymptomatic Infection.
    Koblischke M; Spitzer FS; Florian DM; Aberle SW; Malafa S; Fae I; Cassaniti I; Jungbauer C; Knapp B; Laferl H; Fischer G; Baldanti F; Stiasny K; Heinz FX; Aberle JH
    Front Immunol; 2020; 11():16. PubMed ID: 32038660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural and Functional Characterization of a Cross-Reactive Dengue Virus Neutralizing Antibody that Recognizes a Cryptic Epitope.
    Li J; Watterson D; Chang CW; Che XY; Li XQ; Ericsson DJ; Qiu LW; Cai JP; Chen J; Fry SR; Cheung STM; Cooper MA; Young PR; Kobe B
    Structure; 2018 Jan; 26(1):51-59.e4. PubMed ID: 29249606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A monoclonal antibody to DIII E protein allowing the differentiation of West Nile virus from other flaviviruses by a lateral flow assay.
    Rebollo B; Pérez T; Camuñas A; Pérez-Ramírez E; Llorente F; Sánchez-Seco MP; Jiménez-Clavero MÁ; Venteo Á
    J Virol Methods; 2018 Oct; 260():41-44. PubMed ID: 29958922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-Chikungunya Virus Monoclonal Antibody That Inhibits Viral Fusion and Release.
    Tumkosit U; Siripanyaphinyo U; Takeda N; Tsuji M; Maeda Y; Ruchusatsawat K; Shioda T; Mizushima H; Chetanachan P; Wongjaroen P; Matsuura Y; Tatsumi M; Tanaka A
    J Virol; 2020 Sep; 94(19):. PubMed ID: 32699087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunodominance and functional activities of antibody responses to inactivated West Nile virus and recombinant subunit vaccines in mice.
    Zlatkovic J; Stiasny K; Heinz FX
    J Virol; 2011 Mar; 85(5):1994-2003. PubMed ID: 21147919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural basis for the preferential recognition of immature flaviviruses by a fusion-loop antibody.
    Cherrier MV; Kaufmann B; Nybakken GE; Lok SM; Warren JT; Chen BR; Nelson CA; Kostyuchenko VA; Holdaway HA; Chipman PR; Kuhn RJ; Diamond MS; Rossmann MG; Fremont DH
    EMBO J; 2009 Oct; 28(20):3269-76. PubMed ID: 19713934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. On a mouse monoclonal antibody that neutralizes all four dengue virus serotypes.
    Rajamanonmani R; Nkenfou C; Clancy P; Yau YH; Shochat SG; Sukupolvi-Petty S; Schul W; Diamond MS; Vasudevan SG; Lescar J
    J Gen Virol; 2009 Apr; 90(Pt 4):799-809. PubMed ID: 19264660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancement of anti-DIII antibodies by the C3d derivative P28 results in lower viral titers and augments protection in mice.
    Dunn MD; Rossi SL; Carter DM; Vogt MR; Mehlhop E; Diamond MS; Ross TM
    Virol J; 2010 May; 7():95. PubMed ID: 20462412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.